Document Detail

Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer.
MedLine Citation:
PMID:  23341368     Owner:  NLM     Status:  Publisher    
Enzalutamide, formerly known as MDV3100, is an oral second generation androgen receptor (AR) inhibitor that was chosen from a screen of agents and shown in preclinical studies to have greater affinity for the AR than its predecessors without any agonistic effects. The pre-clinical work that led to the interest in studying this agent and the history of the clinical development of enzalutamide from first in man phase 1 through phase 3 and regulatory approval are reviewed. Information about the toxicity profile and prescribing enzalutamide are discussed in detail. The availability of enzalutamide is put into context with the five other agents that modify survival outcomes in metastatic castration resistant prostate cancer. Some of the new challenges confronting the field regarding sequencing and combinations of these agents and the potential for a change in the natural history of the disease, are also discussed.
Manoj P Menon; Celestia S Higano
Related Documents :
23432698 - The evolving role of vegf-targeted therapies in the treatment of metastatic colorectal ...
23644748 - Engineering of bacterial strains and their products for cancer therapy.
23201598 - Nanoformulation of natural products for prevention and therapy of prostate cancer.
23140488 - Oncolytic reovirus type 3 (dearing) as a novel therapy in head and neck cancer.
15389808 - Association of her-2 polymorphism with japanese sporadic prostate cancer susceptibility.
15734758 - Prolonged hcg action affects angiogenic substances and improves follicular maturation, ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-23
Journal Detail:
Title:  Current oncology reports     Volume:  -     ISSN:  1534-6269     ISO Abbreviation:  Curr Oncol Rep     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888967     Medline TA:  Curr Oncol Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
University of Washington and Fred Hutchinson Cancer Research Center, c/o Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Seattle, WA, 98109, USA,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer.
Next Document:  Subtype CRF01_AE dominate the sexually transmitted human immunodeficiency virus type 1 epidemic in G...